| 产品描述: | FHD-609 is a PROTAC degrader and inhibitor of BRD9 (Bromodomain-containing protein 9). FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment. (Blue: BRD9 ligand-6 , Black: linker ; Pink: (S)-Deoxy-thalidomide-Br ). |
| 靶点: |
BRD9 |
| 体外研究: |
FHD-609 (1mg/kg,静脉注射,每周两次,持续 28 天) 在 SYO-1 异种移植小鼠模型中能够维持 BRD9 降解水平达到 28 天,并表现出抗肿瘤活性[3]。 |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.206 ml |
6.031 ml |
12.063 ml |
| 5 mM |
0.241 ml |
1.206 ml |
2.413 ml |
| 10 mM |
0.121 ml |
0.603 ml |
1.206 ml |
| 50 mM |
0.024 ml |
0.121 ml |
0.241 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |